Meta Information
ID:sermorelin
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/condition/fda-compounding-risk
Target name:
FDA 503B Bulk Drug Substances List
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sermorelin is listed on the FDA's 503B Bulk Drug Substances List (2020). While it was formerly FDA-approved as Geref Diagnostic for GH deficiency evaluation (now discontinued), current clinical use relies on compounded formulations. The FDA 503B listing permits outsourcing facility compounding. Sermorelin is not currently available as an FDA-approved commercial product.
Actionable advice:
The commercial sermorelin product (Geref) is discontinued. Current use relies on 503B-listed compounded preparations. Verify quality and purity of any compounded sermorelin product.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding framework. NOTE/FLAG: sermorelin acetate previously held FDA approval (Geref, for GH-deficiency diagnosis/treatment) and was later withdrawn from marketing; current compounded 'anti-aging' use is off the original indication and unapproved. Verify exact current compounding-list status.
Action type:
avoid
Target id:
/class/corticosteroids
Target name:
Glucocorticoids (Systemic Corticosteroids)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Glucocorticoids suppress GH responses to sermorelin through enhanced somatostatin tone and direct pituitary suppression. This is among the most clinically significant interactions for sermorelin, particularly relevant when sermorelin is used as a diagnostic test for GH deficiency, as false-negative results may occur in patients on systemic corticosteroids.
Actionable advice:
Timing and dosing considerations are required for concurrent use. If using sermorelin diagnostically, systemic corticosteroids should be discontinued before the stimulation test for accurate results. Monitor IGF-1 levels if using sermorelin therapeutically while on corticosteroids.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The GH response to GHRH was significantly blunted in rats pretreated with the synthetic glucocorticoid, dexamethasone, compared to that in normal animals.
Label source:
PubMed: Wehrenberg WB et al., Endocrinology (1990) - glucocorticoids blunt GH via hypothalamic somatostatin (rat) (PMID 1972061)
Action type:
avoid
Target id:
/class/somatostatin-analogs
Target name:
Somatostatin Analogs (e.g., Octreotide, Lanreotide, Pasireotide)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Somatostatin analogs directly antagonize sermorelin's effects by suppressing pituitary GH release at the somatostatin receptor. Co-administration eliminates the GH-stimulating effect of sermorelin, rendering it pharmacologically inert.
Actionable advice:
Sermorelin should not be co-administered with somatostatin analogs. Direct pharmacological antagonism renders sermorelin ineffective.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Octreotide reduced serum GH and plasma GHRH levels in the two patients
Label source:
PubMed: Moller DE et al., J Clin Endocrinol Metab (1989) - the somatostatin analog octreotide suppresses GH and GHRH (PMID 2493033)
Action type:
informational_none
Target id:
/class/thyroid-hormones
Target name:
Thyroid Hormone Replacement (Levothyroxine)
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Hypothyroidism blunts GH responsiveness, reducing the GH-stimulating efficacy of sermorelin. When sermorelin is used diagnostically, thyroid status must be assessed because untreated hypothyroidism can cause a false-negative result on GH stimulation testing.
Actionable advice:
Assess thyroid function (TSH, free T4) before using sermorelin diagnostically. Ensure adequate thyroid replacement before GH axis assessment to avoid false-negative stimulation tests.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Hypothyroidism was associated with a significant reduction in both the peak GH response and the integrated GH secretory response to GHRH compared to those in the euthyroid state
Label source:
PubMed: Williams T et al., J Clin Endocrinol Metab (1985) - hypothyroidism blunts the GH response (PMID 3926807)
Action type:
avoid
Target id:
/class/estrogens
Target name:
Estrogens / estrogen therapy
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sex steroids have complex effects on sermorelin responsiveness. Estrogen enhances GH secretagogue response, while androgens have complex and variable effects on the GH axis. This interaction is relevant when interpreting GH stimulation test results in the context of hormone therapy.
Actionable advice:
Document sex steroid use (including hormone therapy) when interpreting sermorelin GH stimulation test results. Exogenous estrogen may enhance GH response; testosterone effects are variable.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established endocrine physiology: sex steroids (estrogens/androgens) modulate the GH/IGF-1 axis - estrogen tends to blunt the IGF-1 response to GH while androgens augment GH secretion - so concurrent sex-steroid therapy can alter the response to a GHRH analog. Class-level; no sermorelin-specific interaction trial quoted.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/androgens
Target name:
Androgens / testosterone therapy
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sex steroids have complex effects on sermorelin responsiveness. Estrogen enhances GH secretagogue response, while androgens have complex and variable effects on the GH axis. This interaction is relevant when interpreting GH stimulation test results in the context of hormone therapy.
Actionable advice:
Document sex steroid use (including hormone therapy) when interpreting sermorelin GH stimulation test results. Exogenous estrogen may enhance GH response; testosterone effects are variable.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established endocrine physiology: sex steroids (estrogens/androgens) modulate the GH/IGF-1 axis - estrogen tends to blunt the IGF-1 response to GH while androgens augment GH secretion - so concurrent sex-steroid therapy can alter the response to a GHRH analog. Class-level; no sermorelin-specific interaction trial quoted.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/antidiabetic-medications
Target name:
Insulin and Antidiabetic Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GH elevation from sermorelin can transiently induce insulin resistance through increased lipolysis and hepatic glucose production. Sermorelin's GH-stimulating effects may blunt the effectiveness of antidiabetic medications and require dose adjustments. Conversely, hypoglycemia (a potent GH secretagogue stimulus) enhances sermorelin's GH-releasing effect in a favorable feedback loop.
Actionable advice:
Fasting glucose and HbA1c should be monitored during sermorelin therapy in patients with impaired glucose metabolism. Antidiabetic medication doses may require adjustment as GH/IGF-1 levels change.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
GH-axis class effect with mixed direction: GH is counter-regulatory and can reduce insulin sensitivity, but a sermorelin/GHRH-analog trial in older adults (Khorram 1997, PMID 9141536) actually found increased insulin sensitivity in men - so the net glucose effect is dose- and context-dependent. Monitor glucose; do not assume uniform worsening.
Label source:
Class inference
Action type:
adjust_with_prescriber
Target id:
/condition/active-cancer
Target name:
Active Cancer / Malignancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sermorelin elevates GH and IGF-1. IGF-1 is a potent mitogen that can promote tumor growth and metastasis in many cancer types. Active or recent malignancy is a contraindication for sermorelin and all GH secretagogues.
Actionable advice:
Sermorelin should not be used in individuals with active or recent cancer history.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
high serum concentrations of IGF1 are associated with an increased risk of breast, prostate, colorectal, and lung cancers
Label source:
PubMed: Fuerstenberger G & Senn HJ, Lancet Oncol (2002) (PMID 12067807)
Action type:
avoid
Target id:
/biomarker/igf-1
Target name:
IGF-1 Level Monitoring
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sermorelin elevates IGF-1 in a dose-dependent manner through physiological GH axis stimulation. Unlike direct GH administration, sermorelin preserves pituitary feedback regulation, which inherently limits supraphysiological elevation. However, periodic IGF-1 monitoring is still recommended to ensure levels remain within therapeutic range.
Actionable advice:
IGF-1 is best monitored at baseline and every 3 months during sermorelin therapy, targeting the age-appropriate mid-to-upper normal reference range. The preserved feedback regulation of sermorelin provides a natural safety buffer versus exogenous GH.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary.
Label source:
PubMed: Prakash A & Goa KL, BioDrugs (1999) - sermorelin (a GHRH analog) stimulates pituitary GH secretion, raising downstream IGF-1 (PMID 18031173)
Action type:
monitor
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
No safety data exist for sermorelin use during pregnancy or lactation. GH axis modulation during pregnancy carries unknown fetal risks. Use is contraindicated.
Actionable advice:
Sermorelin should not be used during pregnancy or breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
major
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
null
Description:
Sermorelin is designed to amplify the large, natural pulse of growth hormone that occurs during the first few hours of deep, slow-wave sleep.
Actionable advice:
Administer the injection within 30 minutes of going to bed for the night.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Source url:
Exact phrase from label:
Sermorelin is administered once a day, ideally at night.
Label source:
Anecdotal: Healthline
Action type:
informational_none
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2.5
Hours after target:
null
Description:
Elevated blood sugar and fatty acids from food intake trigger the release of somatostatin, a hormone that directly inhibits the pituitary's release of growth hormone, rendering Sermorelin ineffective.
Actionable advice:
Administer on a completely empty stomach, at least 2 to 3 hours after your last meal.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/dietary/high-sugar-foods
Target name:
High-Sugar or High-Carbohydrate Foods
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
3
Hours after target:
null
Description:
A spike in blood glucose is the most potent stimulus for somatostatin release, which will completely block the action of Sermorelin and natural growth hormone release.
Actionable advice:
Strictly avoid sugary foods or large carbohydrate meals for at least 3 hours before your injection.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if Sermorelin passes into breast milk or what its effects on a nursing infant might be. Use is contraindicated.
Actionable advice:
It should be avoided completely while breastfeeding.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
It is unknown if this drug passes into breast milk.
Label source:
Anecdotal: RxList
Action type:
avoid
Target id:
/condition/thyroid-disorders
Target name:
Untreated Thyroid Disorders
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Normal thyroid hormone levels are required for an optimal pituitary response to GHRH; untreated hypothyroidism can significantly blunt Sermorelin's effectiveness.
Actionable advice:
It is a good idea for thyroid function to be tested and optimized before and during therapy for best results.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Untreated hypothyroidism can jeopardize the response to Sermorelin .
Label source:
Anecdotal: RxList
Action type:
informational_none
Target id:
/condition/diabetes-mellitus
Target name:
Uncontrolled Diabetes Mellitus
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Chronically elevated blood glucose levels inhibit growth hormone secretion via somatostatin, which will counteract the intended effects of Sermorelin.
Actionable advice:
Work with your doctor to ensure good glycemic control, as high blood sugar will make Sermorelin less effective.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/class/ghrps-ghrhs
Target name:
Other GH Secretagogues (e.g., Ipamorelin, CJC-1295)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Combining a GHRH (like Sermorelin) with a GHRP (like Ipamorelin) can create a powerful synergistic effect, leading to a much greater HGH pulse than either agent alone.
Actionable advice:
May be combined with other secretagogues like Ipamorelin under medical supervision for an enhanced effect.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/biomarker/fasting-glucose
Target name:
Fasting Glucose
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Growth hormone has a counter-regulatory effect on insulin and can slightly increase blood glucose levels in some individuals.
Actionable advice:
Periodically monitor fasting glucose to ensure therapy is not negatively impacting glycemic control.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Men with conditions like diabetes, sleep apnea, or thyroid disorders may respond differently to therapy and may be advised against starting treatment.
Label source:
Anecdotal: Gameday Men's Health
Action type:
monitor
Target id:
/intervention/resistance-training
Target name:
Resistance Training
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Resistance exercise is a natural stimulus for growth hormone release and can improve tissue sensitivity to IGF-1, enhancing the overall benefits of Sermorelin therapy.
Actionable advice:
Incorporate regular resistance training into your routine to complement the effects of Sermorelin.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Several short-term studies aiming to increase GH in older adults by a variety of interventions including exercise, administration of GH, or treatment with GH secretagogues have demonstrated consistent effects to improve body composition, yet inconsistent effects on physical and cognitive function.
Label source:
Anecdotal: NIH
Action type:
informational_none
Target id:
/class/anticholinergic-medications
Target name:
Anticholinergic Medications
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Theoretically, high-dose anticholinergic drugs may interfere with the neural pathways that regulate GHRH release, potentially blunting the response to Sermorelin.
Actionable advice:
The effect is likely minor, but be aware that strong anticholinergic drugs could slightly reduce Sermorelin's efficacy.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none